retatrutide type 2 diabetes trial 2024 Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 Retatrutide Severe Obesity Trial Shows

The tradeoff is that you're managing two peptides (and, for purchasing, verifying two)

In 2023, a record 10,660 liver transplants were performed in the United States alone, with MASH accounting for 27% of these procedures, making it the second leading indication for liver transplantation

Your metabolism hasn't fundamentally changedyou've only removed the medication that was helping regulate your appetite and satiety signals

Carbohydrates can be adjusted based on activity level and personal response

While both GLP-1 medications and bariatric surgery can support significant weight loss, certain situations may make one option feel like a better fit than the other

This makes it relevant to laboratory investigations involving receptor cross-talk, metabolic adaptation, glucose-associated signaling, appetite-associated pathway biology, energy expenditure models, substrate utilization, hepatic metabolic signaling, and adipose-associated response systems